Product Liability – $2.2 Billion in Drug-Marketing Settlement
November 4, 2013
Health-care behemoth Johnson & Johnson will pay $2.2 billion to resolve civil and criminal allegations involving the marketing of off-label, unapproved uses for several prescription drugs, Justice Department officials announced Monday.The cases include allegations of kickbacks to doctors and pharmacies to promote usage of the anti-psychotic drugs Risperdal and Invega, and a heart-failure drug, Natrecor.
Read more: Johnson & Johnson agrees to pay $2.2 billion in drug-marketing settlement – The Washington Post.
